Please try another search
Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury or failure, and in the areas of unmet medical need. The company was founded in 1998 and is headquartered in Palo Alto, California. As of December 11, 2017, Ocera Therapeutics, Inc. operates as a subsidiary of Mallinckrodt plc. On August 28, 2023, Ocera Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review